page.DEFS += "
"; page.DEFS += "
1. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
2. The Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633-643.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
3. Data on file, DA-ARI-09. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
4. Data on file, DA-ARI-14. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
5. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-2139.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
6. Federman DD. The adrenal. In: Dale DC, Federman DD, eds. Scientific American Medicine. Vol 1. New York, NY: Healtheon/WebMD; 2000.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
7. Goss PE, Gwyn KMEH. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol. 1994;12(11):2460-2470.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
8. Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol. 1996;23(4 suppl 9):33-38.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
9. Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. Am J Clin Oncol (CCT). 1995;18(5):407-417.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
10. Hortobagyi GN, Buzdar AU. Anastrozole (Arimidex®), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. Cancer Invest. 1998;16(6):385-390.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
11. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
12. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556-562.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
13. Schneider PJ, Murphy JE, Pederson CA. Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc. 2008;48(1):58-63.
"; page.DEFS += "
"; page.DEFS += "
"; page.DEFS += "
14. Data on file, DA-ARI-22. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.
"; page.DEFS += "
"; startReference();